Table 1. Characteristics of APOA1 S36A, F71Y, K107del, and L144R heterozygotes and noncarriers in the Copenhagen City Heart Study (n = 10,330) and the Copenhagen General Population study (n = 45,239).
| Copenhagen City Heart Study | Copenhagen General Population study | |||||||||
| Noncarriers | Heterozygotes | Noncarriers | Heterozygotes | |||||||
| S36A | F71Y | K107del | L144R | S36A | F71Y | K107del | L144R | |||
| n = 10,308 | n = 5 | n = 9 | n = 4 | n = 4 | n = 45,141 | n = 29 | n = 48 | n = 9 | n = 12 | |
| Age (years) | 59 (45–69) | 67 (38–37) | 62 (59–68) | 66 (52–70) | 47 (44–62) | 57 (47–67) | 65 (56–71)b | 52 (45–66) | 50 (41–57) | 57 (41–61) |
| Sex (F/M) | 5,738/4,570 | 2/3 | 8/1 | 2/2 | 3/1 | 24,847/20,294 | 23/6b | 32/16 | 4/5 | 8/4 |
| Apolipoprotein A-I (mg/dL) | 140 (123–161) | 106 (106–120)b | 162 (144–169) | 120 (108–148) | 101 (84–118)b | 156 (139–176) | 139 (131–162)a | 142 (130–162)b | 169 (151–172) | 117 (91–125)b |
| HDL cholesterol (mmol/L) | 1.5 (1.2–1.8) | 1.1 (1.0–1.2)a | 1.7 (1.5–1.8) | 1.0 (0.9–1.4)a | 0.8 (0.7–0.9)b | 1.6 (1.3–2.0) | 1.5 (1.3–1.8) | 1.3 (1.1–1.7)b | 1.1 (0.9–1.4)a | 0.7 (0.6–1.0)b |
| Total cholesterol (mmol/L) | 6.0 (5.1–6.9) | 5.0 (4.2–5.7) | 6.7 (6.2–6.9) | 6.9 (6.4–7.9) | 4.7 (4.2–5.4)a | 5.6 (4.9–6.3) | 5.8 (5.4–6.0) | 5.3 (4.4–6.3) | 5.7 (5.5–5.9) | 5.3 (4.1–5.5)a |
| LDL cholesterol (mmol/L) | 3.6 (2.9–4.4) | 3.0 (2.2–3.8) | 3.7 (3.6–4.5) | 4.5 (4.2–5.3)a | 3.2 (2.7–3.4) | 3.2 (2.6–3.8) | 3.3 (2.7–3.8) | 3.0 (2.4–3.9) | 3.3 (3.1–3.8) | 3.4 (3.0–3.7) |
| Triglycerides (mmol/L) | 1.5 (1.1–2.2) | 1.8 (1.8–1.9) | 1.7 (1.4–1.8) | 2.2 (1.5–3.3) | 2.2 (1.2–3.0) | 1.4 (1.0–2.1) | 1.4 (1.2–1.8) | 1.6 (0.8–2.4) | 1.3 (0.8–2.8) | 2.0 (1.1–2.5) |
| Apolipoprotein B (mg/dL) | 86 (71–103) | 70 (64–90) | 93 (89–107) | 102 (96–119) | 78 (69–107) | 107 (88–131) | 112 (96–128) | 99 (83–145) | 120 (102–144) | 118 (99–142) |
| Body mass index (kg/m2) | 25(22–28) | 27(26–28) | 26(22–28) | 28(25–32) | 27(24–29) | 26 (23–29) | 25 (22–28) | 25 (23–27) | 24 (22–26) | 26 (24–28) |
| Lipid lowering therapy (%) | 1 | 0 | 0 | 0 | 0 | 10 | 10 | 13 | 11 | 17 |
| Physical inactivity (%) | 64 | 80 | 56 | 25 | 75 | 52 | 48 | 58 | 67 | 42 |
| Drinking (%) | 57 | 80 | 56 | 25 | 100 | 32 | 28 | 26 | 56 | 25 |
| Smoking (%) | 47 | 20 | 67 | 50 | 25 | 22 | 17 | 28 | 22 | 2 |
| Hypertension (%) | 52 | 80 | 67 | 25 | 50 | 61 | 78 | 56 | 25 | 58 |
| Diabetes (%) | 4 | 20 | 0 | 0 | 0 | 4 | 0 | 4 | 0 | 0 |
Values are median (interquartile range) or percentage. Mann-Whitney U-test or Fishers exact test was used for continuous and categorical traits, respectively. Lipid-lowering therapy was self-reported. Physical inactivity, drinking, smoking, hypertension and diabetes were dichotomized and defined as physical inactivity (less than 2–4 hours per week of light physical activity at leisure time), drinking (more than 1 drink per week), current smoking, hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, and/or use of antihypertensive therapy), and diabetes (self-reported disease, current use of anti-diabetic medication, and/or nonfasting plasma glucose >11.0 mmol/L). LDL cholesterol levels were calculated using the Friedewald equation if triglycerides were ≤4 mmol/L, but measured directly at higher triglyceride levels.
P<0.05;
P<0.01.